PPCB
Propanc Biopharma, Inc. Common Stock
stockNASDAQ
propanc biopharma, inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in australia. its lead product is prp, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. the company has a research collaboration with university of jaã©n to commence the pop1 joint drug discovery program. the company was formerly known as propanc health group corporation and changed its name to propanc biopharma, inc. in april 2017. propanc biopharma, inc. was founded in 2007 and is based in camberwell, australia.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.32 | 2026-10-19 | +660.95% | 6.101 |
| 1M | 0.63 | 2026-09-25 | +282.71% | 4.478 |
| 3M | 1.32 | 2026-07-27 | +82.74% | 5.851 |
| 6M | 2.59 | 2026-04-27 | -6.78% | 4.980 |
| 1Y | 37.00 | 2025-10-27 | -93.48% | 2.828 |
| 2Y | 600.00 | 2024-10-25 | -99.60% | — |
| 5Y | 40,000,000.00 | 2021-10-26 | -100.00% | -0.188 |
Propanc Biopharma, Inc. Common Stock (NASDAQ:PPCB) stock price today is $2.41, and today's volume is 64,806. PPCB is up 761.500% today. The 30 day average volume is 346,425. PPCB market cap is $23.71M with 9.83M shares outstanding.